Evaluation of the pharmacokinetics of pemigatinib in patients with impaired hepatic or renal function
Ji, Tao, Rockich, Kevin, Epstein, Noam, Overholt, Heather, Wang, Phillip, Chen, Xuejun, Punwani, Naresh, Yeleswaram, Swamy
Published in British journal of clinical pharmacology (01.01.2022)
Published in British journal of clinical pharmacology (01.01.2022)
Get full text
Journal Article
Abstract C071: Pharmacokinetics and pharmacodynamics of pemigatinib, a potent and selective inhibitor of FGFR 1, 2, and 3, in patients with advanced malignancies
Ji, Tao, Lihou, Christine, Asatiani, Ekaterine, Féliz, Luis, Overholt, Heather, Landman, Robert, Chen, Xuejun, Yeleswaram, Swamy
Published in Molecular cancer therapeutics (01.12.2019)
Published in Molecular cancer therapeutics (01.12.2019)
Get full text
Journal Article
Correction to: Evaluation of drug‑drug interactions of pemigatinib in healthy participants
Ji, Tao, Rockich, Kevin, Epstein, Noam, Overholt, Heather, Wang, Phillip, Chen, Xuejun, Punwani, Naresh, Yeleswaram, Swamy
Published in European journal of clinical pharmacology (01.12.2021)
Published in European journal of clinical pharmacology (01.12.2021)
Get full text
Journal Article